2seventy bio - 2025 Company Profile & Competitors

Q: Where is 2seventy bio located?

2seventy bio is located in Cambridge, United States .

2seventy bio is an acquired company based in Cambridge (United States), founded in 2021. It operates as a Developer of cellular therapies for the treatment of cancer. The company has 3061 active competitors, including 1090 funded and 707 that have exited. Its top competitors include companies like Moderna, Jazz Pharmaceuticals and BeiGene.

Company Details

Developer of cellular therapies for the treatment of cancer. The company uses multiple engineered cell therapies that combine lentiviral vector, CAR-T, and TCR technologies to address the challenge of tumor control and elimination. The company's flagship product is Abecma for multiple myeloma and focuses on the development of therapies for a broad range of hematologic malignancies.

Website
Social
Email ID: @2seventybio.com
Phone Number: +1
Part Of: regeneron.com

Key Metrics

Founded Year

2021

Location

Cambridge, United States

Stage

Acquired

Ranked

798^th among 3061 active competitors

Annual Revenue

as on Dec 31, 2022

Employee Count

as on Dec 31, 2021

Similar Companies

Jazz Pharmaceuticals &

Exit Details

Acquired by Bristol-Myers Squibb (Mar 11, 2025)

Legal entities associated with 2seventy bio

2seventy bio is associated with 1 legal entity given below:

Legal Entity Name	Date of incorporation	Revenue	Net Profit	Employee Count
	Apr 25, 2021	$91.5M (as on Dec 31, 2022)	238	156

2seventy bio got acquired by Bristol-Myers Squibb on Mar 11, 2025 at an acquisition amount of $286M. It was facilitated by Goldman Sachs and Goodwin.

Click to take a look at 2seventy bio's acquisition in detail

2seventy bio has not raised any funding rounds yet.

Top competitors of 2seventy bio include Moderna, Jazz Pharmaceuticals and BeiGene. Here is the list of Top 10 competitors of 2seventy bio, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Flagship Pioneering, Wellington听&补尘辫;听	86/100
2nd	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of therapeutics for cancer and neurological disorders	$265M	InterWest Partners, Investor Growth Capital听&补尘辫;听	85/100
3rd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	T. Rowe Price, Temasek听&补尘辫;听	83/100
4th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Vivo Capital, HBM Partners听&补尘辫;听	82/100
5th	Recursion 2013, United States, Public	R&D based company focused on manufacturing of drugs for multiple therapeutic areas	$452M	HTIF, Menlo Ventures听&补尘辫;听	81/100
6th	Incyte 1991, Wilmington (United States), Public	Developer of small molecules for the treatment of different cancer and skin diseases	-	Tekla Capital Management, Ridgeback Capital Management听&补尘辫;听	78/100
7th	Revolution Medicines 2014, Redwood City (United States), Public	Developer of therapies for treating cancer	$181M	Vivo Capital, Deerfield听&补尘辫;听	78/100
8th	Blueprint Medicines 2008, Cambridge (United States), Public	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Ridgeback Capital Management, Foresite Capital听&补尘辫;听	76/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Aisling Capital, Frazier Healthcare Partners听&补尘辫;听	76/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Roche, Perceptive Advisors听&补尘辫;听	76/100
798th	2021, Cambridge (United States), Acquired	Developer of cellular therapies for the treatment of cancer	-	-	49/100